Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 11/20 | 0.41 |
| ▸ | HTR6 | P50406 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.30 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.30 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.30 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL616655 | 0.93 | SLC6A9 (0.42) | SLC6A9KCNH2NPY5R | |
| SCHEMBL617952 | 0.92 | SLC6A9 (0.43) | SLC6A9HTR6KCNH2ADRA1D | |
| SCHEMBL615678 | 0.91 | SLC6A9 (0.42) | SLC6A9HTR6SCN8ACARM1PRMT6 | |
| SCHEMBL605130 | 0.90 | SLC6A9 (0.42) | SLC6A9HTR6POLBKCNH2ADRA1D | |
| SCHEMBL614710 | 0.89 | SLC6A9 (0.52) | SLC6A9KCNH2 | |
| SCHEMBL617083 | 0.88 | SLC6A9 (0.49) | SLC6A9KCNH2ADRA1DNPY5R | |
| SCHEMBL614592 | 0.87 | SLC6A9 (0.40) | SLC6A9HTR6POLBKCNH2ADRA1D | |
| SCHEMBL616264 | 0.87 | SLC6A9 (0.34) | SLC6A9HTR6CARM1PRMT6NPY5R | |
| SCHEMBL616999 | 0.85 | HTR6 (0.34) | SLC6A9HTR6CARM1PRMT6NPY5R | |
| SCHEMBL604547 | 0.84 | SLC6A9 (0.44) | SLC6A9HTR6POLBKCNH2ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051280-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-09 | — | — | US | claimed |
| EP-2709987-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott GmbH & Co. KG (DE) | 2014-03-26 | — | — | EP | claimed |
| WO-2012020133-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-02-16 | — | — | WO | claimed |
| US-9051280-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-09 | — | — | US | disclosed |
| US-8883839-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883839-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-11-11 | — | — | US | disclosed |
| US-20120295881-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-11-22 | — | — | US | disclosed |
| WO-2012020133-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-02-16 | — | — | WO | disclosed |
| US-20120040947-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040947-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040947-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC10A1, SUGT1, SLC10A2 | SLC6A9 42/4885HTR6 1604/4885POLB 4252/4885 |
| US-20120295881-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC10A1, SUGT1, SLC10A2 | SLC6A9 42/4885HTR6 1604/4885POLB 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.